Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | CTSV | O60911 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL810439 | 0.87 | PTGES (0.57) | PTGESCTSVCTSLMAPTMEN1 | |
| SCHEMBL30699715 | 0.87 | PTGES (0.57) | PTGESCTSVCTSLMAPTMEN1 | |
| SCHEMBL4233714 | 0.85 | MEN1 (0.53) | PTGESCTSVCTSLMAPTMEN1 | |
| SCHEMBL30002648 | 0.85 | MEN1 (0.53) | PTGESCTSVCTSLMAPTMEN1 | |
| SCHEMBL29034462 | 0.85 | MEN1 (0.53) | PTGESCTSVCTSLMAPTMEN1 | |
| SCHEMBL30002441 | 0.85 | MEN1 (0.53) | PTGESCTSVCTSLMAPTMEN1 | |
| SCHEMBL14484687 | 0.85 | MAPT (0.51) | CTSVCTSLMAPTMEN1KMT2A | |
| SCHEMBL1137268 | 0.85 | PTGES (0.57) | PTGESCTSVCTSLMAPTMEN1 | |
| SCHEMBL810879 | 0.84 | PTGES (0.54) | PTGESMRGPRX4CTSVCTSLMAPT | |
| SCHEMBL3620743 | 0.84 | CTSV (0.48) | PTGESCTSVCTSLMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087602-B2 | Cinnoline derivatives and use as medicine | ASTRAZENECA UK LIMITED (GB) | 2006-08-08 | — | — | US | disclosed |
| EP-0888310-B1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ASTRAZENECA AB (SE) | 2005-09-07 | — | — | EP | disclosed |
| EP-0929526-B1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6809097-B1 | ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY | ZENECA LIMITED (GB) | 2004-10-26 | — | — | US | disclosed |
| US-20030199513-A1 | Cinnoline derivatives and use as medicine | ZENECA LIMITED | 2003-10-23 | — | — | US | disclosed |
| EP-0880508-B1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2003-04-16 | — | — | EP | disclosed |
| US-6514971-B1 | For use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans | ZENECA LIMITED (GB) | 2003-02-04 | — | — | US | disclosed |
| US-6184225-B1 | ENDOTHELIAL GROWTH FACTOR INHIBITORS, ANGIOGENESIS INHIBITORS | ZENECA LIMITED (GB) | 2001-02-06 | — | — | US | disclosed |
| EP-0929526-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| EP-0888310-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1999-01-07 | — | — | EP | disclosed |
| EP-0880508-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| WO-1998013350-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
| WO-1997034876-A1 | CINNOLINE DERIVATIVES AND USE AS MEDICINE | ZENECA LIMITED (GB) | 1997-09-25 | — | — | WO | disclosed |
| WO-1997030035-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ZENECA LIMITED (GB) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199513-A1 | Cinnoline derivatives and use as medicine | VEGFA, CNR1, CCR7 | PTGES 1922/4885MRGPRX4 830/4885CTSV 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.